Gary A Beaudry from Orlando, FL, age 69

Us Patents

Cd4-Gamma2 And Cd4-Igg2 Chimeras
view source
US Patent:

6451313, Sep 17, 2002
Filed:

Jun 7, 1995
Appl. No.:

08/484681
Inventors:

Paul J. Maddon - New York NY
Gary A. Beaudry - Upper Montclair NJ
Assignee:

Progenics Pharmaceuticals, Inc. - Tarrytown NY
International Classification:

A61K 3817
US Classification:

4241851, 424 149, 424 169, 4241341, 4241841, 4241921, 435 691, 435 697, 435328, 435358, 435361, 435365, 530350, 5303873
Abstract:

This invention provides an expression vector encoding a CD4-gamma2 chimeric heavy chain homodimer. This invention also provides an expression vector encoding the heavy chains of a CD4-IgG2 chimeric heterotetramer. Finally, this invention provides an expression vector encoding the light chains of a CD4-IgG2 chimeric heterotetramer.

Cells Expressing A Cd4-Igg2 Chimeric Heterotetramer
view source
US Patent:

7070991, Jul 4, 2006
Filed:

Jun 7, 1995
Appl. No.:

08/485163
Inventors:

Gary A. Beaudry - Upper Montclair NJ, US
Paul J. Maddon - New York NY, US
Assignee:

Progenics Pharmaceuticals, Inc. - Tarrytown NY
International Classification:

C12N 5/10
C12N 15/12
C12N 15/63
US Classification:

435325, 435455, 4352523, 435 361, 530350, 5303873, 536 231, 536 234, 536 235, 536 2353
Abstract:

This invention provides an expression vector encoding a CD4-gamma2 chimeric heavy chain homodimer. This invention also provides an expression vector encoding the heavy chains of a CD4-IgG2 chimeric heterotetramer. Finally, this invention provides an expression vector encoding the light chains of a CD4-IgG2 chimeric heterotetramer.

Methods For The Diagnosis And Treatment Of Lung Cancer
view source
US Patent:

7846667, Dec 7, 2010
Filed:

Aug 20, 2009
Appl. No.:

12/545028
Inventors:

Jin Jen - Baltimore MD, US
Gary A. Beaudry - Montclair NJ, US
Stephen L. Madden - Sudbury MA, US
Arthur H. Bertlesen - Ridgewood NJ, US
David Sidransky - Baltimore MD, US
Assignee:

Genzyme Corporation - Framingham MA
Johns Hopkins University - Baltimore MD
International Classification:

C12Q 1/68
US Classification:

435 6, 435 71, 536 235, 536 2431, 536 2433, 530350, 5303871, 5303877, 436 64
Abstract:

The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.

Methods For The Diagnosis And Treatment Of Lung Cancer
view source
US Patent:

8067240, Nov 29, 2011
Filed:

Nov 22, 2010
Appl. No.:

12/951449
Inventors:

Jin Jen - Baltimore MD, US
Gary A. Beaudry - Nutley NJ, US
Stephen L. Madden - Sudbury MA, US
Arthur H. Bertlesen - Ridgewood NJ, US
David Sidransky - Baltimore MD, US
Assignee:

Esoterix Genetic Laboratories, LLC - Burlington NC
Johns Hopkins University School of Medicine - Baltimore MD
International Classification:

G01N 33/50
US Classification:

436 64, 435 6, 435 71, 435 723, 530350, 536 235, 536 243
Abstract:

The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.

Compositions And Methods For The Identification Of Lung Tumor Cells
view source
US Patent:

20040166527, Aug 26, 2004
Filed:

Apr 1, 2004
Appl. No.:

10/816079
Inventors:

Gary Beaudry - Nutley NJ, US
Stephen Madden - Sudbury MA, US
Arthur Bertelsen - Ridgewood NJ, US
International Classification:

C12Q001/68
G01N033/574
C07H021/04
C12N005/08
US Classification:

435/006000, 435/007230, 435/069100, 435/320100, 435/366000, 530/350000, 536/023500
Abstract:

This invention provides compositions and methods for the identification of lung cancer cells. In particular, polynucleotide sequences whose presence is indicative of lung cancer are disclosed. In addition, lung cancer can be identified by detecting the presence of the peptides encoded by these sequences. Antibodies to these peptides are also provided. Also included are gene delivery vehicles and host cells comprising these polynucleotides. Kits containing agents and instructions necessary to perform the screening and detecting methods are also provided.

Methods For The Diagnosis And Treatment Of Lung Cancer
view source
US Patent:

20070218511, Sep 20, 2007
Filed:

Aug 14, 2006
Appl. No.:

11/504260
Inventors:

Jin Jen - Baltimore MD, US
Gary Beaudry - Montclair NJ, US
Stephen Madden - Sudbury MA, US
Arthur Bertlesen - Ridgewood NJ, US
David Sidransky - Baltimore MD, US
International Classification:

G01N 33/574
C12N 5/08
G01N 33/48
US Classification:

435007230, 435375000, 436063000
Abstract:

The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell, and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition.

Vectors And Vector Systems Including Genes Encoding Tumor Suppressor Proteins And Producer Cells Transformed Thereby
view source
US Patent:

57006571, Dec 23, 1997
Filed:

Dec 13, 1993
Appl. No.:

8/166297
Inventors:

Gary A. Beaudry - Montclair NJ
Arthur H. Bertelsen - Ridgewood NJ
Michael I. Sherman - GlenRidge NJ
Bert Vogelstein - Baltimore MD
Assignee:

Genzyme Corporation - Framingham MA
International Classification:

C12P 2102
C12P 1934
C12N 510
C12N 701
US Classification:

435 691
Abstract:

Vectors and vector systems are embodied that include a gene encoding a tumor suppressor protein. In one embodiment, the vector includes a gene encoding a tumor suppressor protein and an inducible promoter controlling the gene encoding a tumor suppressor protein. The tumor suppressor protein may be p53 protein. In another embodiment, there is provided a vector system which comprises a first vector including a gene encoding a tumor suppressor protein, and a second vector containing a nucleic acid sequence encoding an antisense sequence complementary to all or a portion of the gene encoding a tumor suppressor protein. In yet another embodiment, there is provided a vector system which comprises a first vector including a gene encoding a tumor suppressor protein, and a second vector containing a gene which encodes a protein which binds to, and thereby inhibits, the tumor suppressor protein. Such vectors and vector systems enable cells transformed thereby to continue to proliferate such that adequate amounts of infectious viral particles, generated from viral vectors including a gene encoding a tumor suppressor protein, can be harvested for administration to patients.

Uses Of Cd4-Gamma2 And Cd4-Igg2 Chimeras
view source
US Patent:

61877484, Feb 13, 2001
Filed:

Jun 7, 1995
Appl. No.:

8/485372
Inventors:

Paul J. Maddon - New York NY
Gary A. Beaudry - Upper Montclair NJ
Assignee:

Progenics Pharmaceuticals, Inc. - Tarrytown NY
International Classification:

A61K 3800
C12N 1562
US Classification:

514 12
Abstract:

This invention provides the CD4-IgG2 chimeric heterotetramer, wherein the heavy chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193). This invention also provides the CD4-IgG2 chimeric heterotetramer, wherein the light chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194). This invention also provides the CD4-IgG2 chimeric heterotetramer, wherein the heavy chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193) and the light chains of the chimeric heterotetramer is encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194). Finally, this invention provides a method of inhibiting HIV infection of a CD4+ cell, a method of preventing a subject from being infected with HIV, and a method of treating a subject infected with HIV so as to block the spread of HIV infection, using the above CD-4-IgG2 chimeric heterotetramers.